Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Hall

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology and Therapeutics|March 4, 2006
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substratesGirum L Lemma, Zaiqi Wang, Mitchell A Hamman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2025
Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolidesLuc R A Rougée, Pooja V Hegde, Kaitlin Shin, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|January 26, 2010
GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke--a case reportStephen D Hall, Naoki Yamawaki, Alison E Fisher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 9, 2010
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177Yoninah S Cramer, Susan L Rosenkranz, Stephen D Hall, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 30, 2012
QT effect of semagacestat at therapeutic and supratherapeutic dosesWei Zhang, Mosun Ayan-Oshodi, Brian A Willis, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2003
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activityBryan A Ward, J Christopher Gorski, David R Jones, et al.
Headache|March 12, 2004
Spatio-temporal imaging of cortical desynchronization in migraine visual aura: a magnetoencephalography case studyStephen D Hall, Gareth R Barnes, Arjan Hillebrand, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 3, 2009
Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in ratsXin Zhang, Raymond E Galinsky, Robert E Kimura, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2024
Heterotropic Allosteric Modulation of CYP3A4 In Vitro by Progesterone: Evidence for Improvement in Prediction of Time Dependent Inhibition for MacrolidesLuc R A Rougee, Pooja V Hegde, Kaitlin Shin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2013
The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbineAriel R Topletz, Jennifer B Dennison, Robert J Barbuch, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology and Therapeutics|March 4, 2006
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substratesGirum L Lemma, Zaiqi Wang, Mitchell A Hamman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 30, 2025
Heterotropic allosteric modulation of CYP3A4 in vitro by progesterone: Evidence for improvement in prediction of time-dependent inhibition for macrolidesLuc R A Rougée, Pooja V Hegde, Kaitlin Shin, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|January 26, 2010
GABA(A) alpha-1 subunit mediated desynchronization of elevated low frequency oscillations alleviates specific dysfunction in stroke--a case reportStephen D Hall, Naoki Yamawaki, Alison E Fisher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 9, 2010
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177Yoninah S Cramer, Susan L Rosenkranz, Stephen D Hall, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 30, 2012
QT effect of semagacestat at therapeutic and supratherapeutic dosesWei Zhang, Mosun Ayan-Oshodi, Brian A Willis, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2003
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activityBryan A Ward, J Christopher Gorski, David R Jones, et al.
Headache|March 12, 2004
Spatio-temporal imaging of cortical desynchronization in migraine visual aura: a magnetoencephalography case studyStephen D Hall, Gareth R Barnes, Arjan Hillebrand, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 3, 2009
Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in ratsXin Zhang, Raymond E Galinsky, Robert E Kimura, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2024
Heterotropic Allosteric Modulation of CYP3A4 In Vitro by Progesterone: Evidence for Improvement in Prediction of Time Dependent Inhibition for MacrolidesLuc R A Rougee, Pooja V Hegde, Kaitlin Shin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2013
The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbineAriel R Topletz, Jennifer B Dennison, Robert J Barbuch, et al.
Pageof 14